Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, Martin AA. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017 Dec;8(6):1365-78. doi: 10.1007/s13300-017-0326-8
Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, Deeg MA. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. Diabetes Ther. 2013 Dec;4(2):443-59. doi: 10.1007/s13300-013-0046-7.
Hirsch IB, Xu Y, Davis KL, Calingaert B. Patient factors associated with glucagonlike peptide 1 receptor agonist use with and without insulin. Endocr Pract. 2011 Sep 1;17(5):707-16.
Tunceli K, Pladevall-Vila M, Williams LK, Divine GW, Simpkins JC, Nag SS, Sajjan SG, Kamal-Bahl SJ, Alexander CM, Lafata JE. Trends in lipid management among patients with diabetes. Endocr Pract. 2006 Jul;12(4):380-7.